FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Home
/
insight
/
details

Decoding Genetic Puzzles: The Enigma of Variants of Uncertain Significance (VUS)

NextEdge Admin

15 Jan 2024

3 min 17 sec

In the genetic world, the term “VUS” stands for “Variant of Uncertain Significance.” Variants of uncertain significance are genetic alterations or mutations that are identified during genetic testing but whose impact on an individual’s health is not well understood. The interpretation of genetic variants is crucial aspect of genetic testing, especially in the context of clinical genetics and personalized medicine.

Genetic Testing: Genetic testing involves the analysis of an individual’s DNA to identify genetic variants or mutations. This can be done for various purposes, such as diagnosing genetic disorders, assessing the risk of developing certain conditions, or informing treatment decisions.

Types of Genetic Variants: Pathogenic: Variants that are clearly associated with a disease or health condition. Benign: Variants that are harmless and do not contribute to disease. Variant of Uncertain Significance (VUS): Variants for which the significance in terms of disease risk or health impact is unclear.

Uncertain Significance: A VUS may arise when a genetic variant is identified, but there is insufficient evidence or knowledge about its role in causing or contributing to a specific condition. Advances in genetic research and ongoing studies may lead to reclassification of VUS over time as more information becomes available.

Clinical Implications: The presence of a VUS can pose challenges for clinicians and individuals undergoing genetic testing. It may not provide clear guidance for medical management or treatment decisions. Clinicians often consider a combination of factors, including family history, clinical presentation, and additional testing, to assess the overall risk associated with a VUS.

Genetic Counseling: Genetic counselors play a crucial role in helping individuals and families understand the implication of genetic testing results, including VUS. Counseling may involve explaining the uncertainty associated with the variant, discussing potential health implications, and addressing the psychological and emotional aspects of uncertain genetic information.

Research and Reevaluation :Ongoing research in the field of genetics can lead to new insights into the significance of previously uncertain variants. Laboratories and researchers periodically reevaluate VUS as more data becomes available.